Company intelligence / Profile preview
BlueSphere Bio
Pittsburgh, Pennsylvania, United Statesbluespherebio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Received IND clearance from FDA for first-in-human candidate BSB-1001, a TCR T-cell therapy targeting high-risk leukemia. Established strategic collaboration with the National Cancer Institute to advance treatments for rare respiratory disease.
- Therapeutic areas
- OncologyRare DiseasesHematology
- Modalities
- T-cell receptor (TCR) T-cell therapy
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
National Cancer Institute (NCI)Johnson & Johnson Innovation - JLABS (virtual member)
Beyond the preview
Go deeper on BlueSphere Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BlueSphere Bio.